Development of Nav1.1 Enhancers to Treat Alzheimer's Disease

开发 Nav1.1 增强剂来治疗阿尔茨海默病

• 批准号: 10801495
• 负责人: Michael Pleiss
• 金额: $ 5万
• 依托单位: CURE NETWORK DOLBY ACCELERATION PARTNERS LLC
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-03-15 至 2024-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10801495
• 关键词: Alzheimer' s Disease; Alzheimer' s disease model; Alzheimer' s disease patient; Amyloid; Animal Model; Astrocytes; Behavioral; Biological Availability; Brain; Cell Line; Chemicals; Cognitive; Deposition; Development; Dose; Drug Kinetics; Enhancers; Event; Future; Genetic; Grant; Human; Hyperactivity; Impaired cognition; Inflammation; Interneurons; Link; Microglia; Mus; Nerve Degeneration; Pathogenicity; Pathologic; Patients; Pharmaceutical Chemistry; Pharmacologic Substance; Pre-Clinical Model; Property; SCN1A protein; Sensory; Slice; Small Business Innovation Research Grant; Sodium Channel; Toxic effect; Wild Type Mouse; design; drug candidate; drug development; genome-wide; improved; in vivo; intraperitoneal; mouse model; network dysfunction; neuropathology; neurovascular; novel; novel drug class; optogenetics; overexpression; phase 1 study; phase 2 study; pre-clinical; prevent; restoration; side effect; small molecule; small molecule therapeutics; tau Proteins; tau aggregation; transcriptomics; voltage

ABSTRACT CNDAP is developing a new class of drugs, acting through a unique mechanism of action, to reverse early pathophysiological and cognitive alterations in Alzheimer’s disease (AD). Recent studies indicate that network dysfunction, which includes network hyperactivity, altered oscillatory rhythms, and hyper- synchronized networks, is an early pathogenic event found in preclinical models of AD and in patients with early stages of AD. Network dysfunction contributes to cognitive abnormalities, A and tau accumulation, and neurodegeneration. In animal models, network dysfunction can be restored by enhancing inhibitory (GABAergic) interneuron-dependent gamma rhythms via optogenetic/sensory stimulation or genetic overexpression of Nav1.1. This restoration of gamma rhythms in the AD models leads to reduced amyloid and tau deposition, neurodegeneration, microglia and astrocytic activation, inflammation, neurovascular alterations, AD-induced genome-wide transcriptomics changes, altered oscillatory activity, and cognitive decline. Because overexpression of the sodium channel Nav1.1 by as little as 25% restores gamma rhythms to normal levels in AD models, we are developing small molecule therapeutics designed to safely increase Nav1.1 activity in the brain to treat AD. We have identified several small molecule chemotypes that effectively enhance human Nav1.1 currents in cell lines and interneuron-dependent gamma oscillations in brain slices. Systemic intraperitoneal administration of high doses of a Nav1.1 enhancer in vivo in mice produced no overt toxicity or behavioural side effects but significantly increased endogenous gamma oscillatory activity in wildtype mice, suggesting that our compounds are brain penetrant and may have beneficial effects following systemic administration. In this fast-track SBIR grant, we propose to further develop Nav1.1 enhancers to treat AD. In Phase 1 studies, we will employ medicinal chemistry and SAR analysis to identify structurally unique, potent and selective Nav1.1 enhancers to expand our chemical composition of matter. Pharmacokinetics and brain bioavailability analyses will be used to select the most active compounds with optimal pharmaceutical properties. Our milestone to achieve to move to Phase 2 studies is the identification of at least one structurally novel Nav1.1 enhancer that selectively and significantly increases gamma oscillations ex vivo in brain. Phase 2 studies are designed to establish the ex vivo and in vivo efficacy of our Nav1.1 enhancers to restore network dysfunction in preclinical AD mouse models by their ability to prevent network hypersynchrony and abnormal oscillatory activity, restore genome-wide transcriptomic changes and to reduce cognitive impairment, neuropathology and improve survival to support their future development to treat AD patients.

摘要 CNDAP正在开发一类新的药物，通过独特的作用机制发挥作用， 阿尔茨海默病（AD）的病理生理学和认知改变。最近的研究表明 网络功能障碍，包括网络过度活跃、振荡节律改变和过度兴奋。 同步网络，是在AD临床前模型和AD患者中发现的早期致病事件。 早期AD。网络功能障碍导致认知异常、A β和tau积累， 神经变性在动物模型中，网络功能障碍可以通过增强抑制作用来恢复。 通过光遗传学/感觉刺激或遗传的（GABA能）神经元间依赖性γ节律 Nav1.1的过度表达。AD模型中γ节律的恢复导致淀粉样蛋白减少 和tau沉积、神经变性、小胶质细胞和星形胶质细胞活化、炎症、神经血管 改变，AD诱导的全基因组转录组学变化，改变的振荡活动，和认知 下降因为钠离子通道Nav1.1过表达25%就能恢复伽马节律， 在AD模型中，我们正在开发小分子疗法，旨在安全地增加 Nav1.1在大脑中的活性来治疗AD。我们已经确定了几种有效的小分子化学型 增强细胞系中的人Nav1.1电流和脑切片中的神经元间依赖性伽马振荡。 在小鼠体内全身腹膜内给予高剂量的Nav1.1增强子， 毒性或行为副作用，但显著增加内源性γ振荡活性， 野生型小鼠，这表明我们的化合物是脑渗透剂，并可能具有有益的影响， 系统管理。在这项快速SBIR拨款中，我们建议进一步开发Nav1.1增强剂， 治疗AD。在1期研究中，我们将采用药物化学和SAR分析， 独特的，有效的和选择性的Nav1.1增强剂，以扩大我们的物质的化学组成。 药代动力学和脑生物利用度分析将用于选择最具活性的化合物， 最佳的药物特性。我们进入II期研究的里程碑是确定 至少一种结构新颖的Nav1.1增强子， 大脑中的离体振荡。2期研究旨在确定我们的药物的离体和体内功效。 Nav1.1增强剂通过其预防AD的能力来恢复临床前AD小鼠模型中的网络功能障碍 网络超同步和异常振荡活动，恢复全基因组转录组的变化， 减少认知障碍，神经病理学和提高生存率，以支持他们未来的发展， 治疗AD患者。